Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development

HUGO Journal

Volumn 3, Issue 1, 2009, Pages 31-40

  Liu, Jianjun ^a   Desai, Kartiki Vasant ^a   Li, Yuqing ^a   Banu, Shakeela ^a   Lee, Yew Kok ^a   Qu, Dianbo ^a   Heikkinen, Tuomas ^b   Aaltonen, Kirsimari ^b   Muranen, Taru A ^b   Kajiji, Tasneem Shabbir ^a   Bonnard, Carine ^a   Aittomäki, Kristiina ^b   von Smitten, Karl ^b   Blomqvist, Carl ^b,d   Hopper, John L ^e   Southey, Melissa C ^e   Brauch, Hiltrud ^f   Chenevix Trench, Georgia ^g   Beesley, Jonathan ^g   Spurdle, Amanda B ^g   Chen, Xiaoqing ^g   Czene, Kamila ^c   Hall, Per ^c   Nevanlinna, Heli ^b   Liu, Edison T ^a   more..

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Breast cancer susceptibility; ER negative tumors; P53 binding sites; Polymorphism; PRKAG2 gene

Indexed keywords

EID: 77951637895     PISSN: 18776558     EISSN: 18776566     Source Type: Journal    
DOI: 10.1007/s11568-010-9138-x     Document Type: Article

References (27)

1. Ahmed S, Thomas G et al (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23. 2. Nat Genet 41(5): 585-590.
2. Bond GL, Hu W et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5): 591-602.
3. Bourque G, Leong B et al (2008) Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res 11: 1752-1762.
4. Cawley S, Bekiranov S et al (2004) Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116(4): 499-509.
5. Dunning AM, Healey CS et al (2009) Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 18(6): 1131-1139.
6. Easton DF, Pooley KA et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148): 1087-1093.
7. Fullwood MJ, Liu MH et al (2009). An oestrogen-receptor-α-bound human chromatin interactome. Nature (in press).
8. Hu Z, Jin G et al (2007) MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 16(12): 2717-2723.
9. Inoki K, Zhu T et al (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115(5): 577-590.
10. Jones RG, Plas DR et al (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18(3): 283-293.
11. King MC, Wilson AC (1975) Evolution at two levels in humans and chimpanzees. Science 188(4184): 107-116.
12. Knight JC (2005) Regulatory polymorphisms underlying complex disease traits. J Mol Med 83(2): 97-109.
13. Laderoute KR, Amin K et al (2006) 5′-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 26(14): 5336-5347.
14. Menendez D, Inga A et al (2007) A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. Mol Cell Biol 27(7): 2590-2600.
15. Miller LD, Smeds J et al (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102(38): 13550-13555.
16. Olivier M, Goldgar DE et al (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63(20): 6643-6650.
17. Pastinen T, Hudson TJ (2004) Cis-acting regulatory variation in the human genome. Science 306(5696): 647-650.
18. Pietsch EC, Humbey O et al (2006) Polymorphisms in the p53 pathway. Oncogene 25(11): 1602-1611.
19. Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18(6): 598-608.
20. Shaw RJ, Kosmatka M et al (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101(10): 3329-3335.
21. Sladek R, Hudson TJ (2006) Elucidating cis- and trans-regulatory variation using genetical genomics. Trends Genet 22(5): 245-250.
22. Tan J, Zhuang L et al (2005) Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 65(19): 9012-9020.
23. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2(8): 594-604.
24. Wei CL, Wu Q et al (2006) A global map of p53 transcription-factor binding sites in the human genome. Cell 124(1): 207-219.
25. Weinmann AS, Farnham PJ (2002) Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods 26(1): 37-47.
26. Wells J, Farnham PJ (2002) Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. Methods 26(1): 48-56.
27. Wray GA (2007) The evolutionary significance of cis-regulatory mutations. Nat Rev Genet 8(3): 206-216.